Biomarker Analysis in Post-COVID Patients

University Hospital, Bonn48 enrolled

Overview

Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.

Measurements of neuronal and glial markers in CSF were performed on a SIMOA analyzer (Quanterix) using the Neurology 4-Plex A (Nf-L, Tau, GFAP, UCH-L1) kit.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Post-COVID-19 Syndrome

Interventions

no interventionOTHER

no intervention

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of COVID, Parkinson's disease, primary headache, Multiples Sclerosis, facial paralysis * Persistent post-COVID-19 headache after 3 months of infection * Post COVID-patients without persistent headache * must be able to perform lumbar puncture Exclusion criteria * unknown history of COVID infection * lumbar puncture not possible

Locations (1)

Laura de Boni

Bonn, Germany

Outcomes

Primary Outcomes

Biomarker analysis in CSF

Levels of Nf-L, Tau, GFAP, UCH-L1 in CSF

Time frame: after 3 months of initial infection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.